E
Sell
11/4/2024Downgrade
MindBio Therapeutics Corp. (MBIO) was downgraded to E+ from D- on 11/4/2024 due to a significant decline in the growth index, efficiency index and total return index. EBIT declined 477.62% from $120.2 to -$453.9, net income declined 445.15% from $50.5 to -$174.3, and earnings per share declined from $0.0004 to -$0.0013.
D
Sell
7/29/2024Downgrade
MindBio Therapeutics Corp. (MBIO) was downgraded to D- from D on 7/29/2024 due to a decline in the volatility index and total return index.
D
Sell
6/3/2024Upgraded
MindBio Therapeutics Corp. (MBIO) was upgraded to D from D- on 6/3/2024 due to an increase in the total return index.
D
Sell
5/24/2024Upgraded
MindBio Therapeutics Corp. (MBIO) was upgraded to D- from E+ on 5/24/2024 due to a noticeable increase in the total return index, growth index and efficiency index. EBIT increased 624.1% from $16.6 to $120.2, net income increased 293.49% from -$26.1 to $50.5, and earnings per share increased from -$0.0003 to $0.0004.
E
Sell
2/12/2024None
MindBio Therapeutics Corp. (MBIO) was downgraded to E+ from U on 02/12/2024.
